In every successful intervention, critical insight and careful orchestration between imaging, treatment planning, and live guidance play a vital role. You must be able to spot all tumors including those on the periphery of the organ, easily access them, deliver targeted embolization/ablation, and finally, determine procedural success in the shortest time possible. Philips offers an integrated set of technologies designed explicitly to support you during your interventional oncology procedures. We aim to remove the barriers to efficient and reproducible treatment through step-by-step guidance, full table side control and groundbreaking visualization techniques. Our portfolio supports consistency and precision which leads to superior care and confident performance.
Philips Onco suite is a combination of our latest image-guided therapy solution, the Azurion platform with its interventional solutions, workflow options, education, and services. It provides a comprehensive solution for planning and guidance of embolization as well as biopsy and ablation procedures.

Experiences using Philips Azurion at St. Antonius Hospital, Nieuwegein, The Netherlands

Introducing the new generation of Philips Azurion

Philips Azurion 7 M20 with FlexArm
Solutions for effective guidance in treatment and decision making for tumor embolization offered by Philips image-guided therapy.
Click here to learn moreExplore Philips advanced image-guided therapy solutions for tumor biopsy and ablation, offering precision, efficiency, and improved patient outcomes. Learn more about our innovative technologies for interventional oncology.
Click here to learn moreI needed a partner who shared the vision to grow my oncology practice and could offer cutting-edge technology to support superior patient care today and for procedures of the future "
Ahmed Kamel Abdel Aal
MD, PhD, FSIR, Professor of Interventional Radiology
Complete the form and we will get back to you.
You are now exiting the Philips United States (US) site and entering the Philips global site. This content is intended for a global audience. It may not apply to the US and should not be interpreted as meeting US standards, executive orders or regulations.
Continue